Roshi Gulati
Family Medicine · West Dundee, ILNPI 1922290816
Payments from drug & device makers
Across 266 payments — averaging $13.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$603
- GSK$497
- AstraZeneca$327
- Novartis$305
- Amgen$213
- Boehringer Ingelheim$199
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,517100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $603 |
| GSK | 40 | $497 |
| AstraZeneca | 18 | $327 |
| Novartis | 15 | $305 |
| Amgen | 18 | $213 |
| Boehringer Ingelheim | 23 | $199 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $185 |
| Pfizer | 7 | $143 |
| Merck | 16 | $143 |
| Sanofi-aventis U.S. LLC | 9 | $137 |
| Lilly USA, LLC | 20 | $134 |
| Eisai Inc. | 9 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $101 |
| Amarin Pharma, Inc. | 5 | $89 |
| Regeneron Healthcare Solutions, Inc. | 6 | $86 |
| Mylan Specialty L.p. | 5 | $85 |
| Sunovion Pharmaceuticals Inc. | 4 | $57 |
| Johnson & Johnson | 3 | $56 |
| Shire North American Group Inc | 1 | $16 |
| AbbVie | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$108
- NURTEC ODT$101
How this compares
$3,532 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $91,211 |
| TrulicityDulaglutide | 54 | $68,328 |
| OzempicSemaglutide | 42 | $41,805 |
| EliquisApixaban | 25 | $30,161 |
| MounjaroTirzepatide | 23 | $28,801 |
| FarxigaDapagliflozin Propanediol | 15 | $22,066 |
| LinzessLinaclotide | 17 | $11,198 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,745 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,098 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,993 |
| VascepaIcosapent Ethyl | 19 | $5,241 |
| Atorvastatin Calcium | 416 | $3,934 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $3,837 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $2,856 |
| Metoprolol Succinate | 210 | $2,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $134 | $97,12977 claims |
| Boehringer IngelheimJardiance | $199 | $91,21163 claims |
| Novo NordiskOzempic | $603 | $41,80542 claims |
| PfizerEliquis | $143 | $30,16125 claims |
| AstraZenecaFarxiga | $327 | $22,06615 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $497 | $13,84325 claims |
| AbbVieLinzess, Synthroid | $14 | $12,78837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in West Dundee
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.